Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia
- PMID: 17367957
- DOI: 10.1016/j.mehy.2007.01.047
Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia
Abstract
In the last two decades of angiogenesis research, a variety of angiogenic regulators have been identified. The discovery of several antiangiogenic factors has led to the development of novel ophthalmic therapies. Pterygia are characterized by the encroachment of a fleshy fibrovascular tissue from the bulbar conjunctiva onto the cornea. The pathogenesis of pterygia is presently uncertain and its treatment is quiet controversial. It has also been postulated that the development of pterygia depends on a changed angiogenic stimulator-to-inhibitor ratio. On of the most important known mediators of angiogenesis in pterygia is vascular endothelial growth factor (VEGF). In this article, we briefly review the evidences supporting involvement of vascular endothelial growth factor (VEGF) in the pathogenesis of pterygia and then based on these evidences, we hypothesize that local application of bevacizumab, a monoclonal antibody against VEGF, may inhibit neovascularization and thus, may stop the progression or prevent the recurrence of pterygia.
Similar articles
-
Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment.Semin Ophthalmol. 2009 May-Jun;24(3):130-4. doi: 10.1080/08820530902801106. Semin Ophthalmol. 2009. PMID: 19437347 Review.
-
Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.Nat Clin Pract Gastroenterol Hepatol. 2008 May;5(5):250-67. doi: 10.1038/ncpgasthep1097. Epub 2008 Apr 1. Nat Clin Pract Gastroenterol Hepatol. 2008. PMID: 18382435 Review.
-
Treatment of inflamed pterygia or residual pterygial bed.Br J Ophthalmol. 2009 Jul;93(7):864-5. doi: 10.1136/bjo.2008.155291. Br J Ophthalmol. 2009. PMID: 19553512
-
Bevacizumab (avastin) in ocular processes other than choroidal neovascularization.Ocul Immunol Inflamm. 2009 Mar-Apr;17(2):109-17. doi: 10.1080/09273940802596534. Ocul Immunol Inflamm. 2009. PMID: 19412873 Review.
-
Therapeutic potential of bevacizumab (Avastin) in herpetic stromal keratitis (HSK).Med Hypotheses. 2007;69(3):568-70. doi: 10.1016/j.mehy.2007.01.032. Epub 2007 Mar 21. Med Hypotheses. 2007. PMID: 17368959
Cited by
-
Corneal neovascularization: an anti-VEGF therapy review.Surv Ophthalmol. 2012 Sep;57(5):415-29. doi: 10.1016/j.survophthal.2012.01.007. Surv Ophthalmol. 2012. PMID: 22898649 Free PMC article. Review.
-
Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.Mol Vis. 2011 Jan 11;17:104-12. Mol Vis. 2011. PMID: 21245949 Free PMC article.
-
Subconjunctival bevacizumab in the impending recurrent pterygia.Int Ophthalmol. 2014 Jun;34(3):541-7. doi: 10.1007/s10792-013-9852-1. Epub 2013 Sep 12. Int Ophthalmol. 2014. PMID: 24026871
-
YKL-40 expression in pterygium: a potential role in the pathogenesis.Int Ophthalmol. 2019 Jul;39(7):1445-1450. doi: 10.1007/s10792-018-0957-4. Epub 2018 Jun 19. Int Ophthalmol. 2019. PMID: 29922975
-
Preoperative subconjunctival combined injection of bevacizumab and mitomycin C before the surgical excision of primary pterygium: clinical and histological results.Clin Ophthalmol. 2017 Mar 10;11:493-501. doi: 10.2147/OPTH.S127700. eCollection 2017. Clin Ophthalmol. 2017. PMID: 28331283 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical